Form 4: Heron Therapeutics CEO Converts RSUs to Common Stock

Heron Therapeutics CEO Craig Collard converted 34,789 restricted stock units into common stock, increasing his direct beneficial ownership.

Summary

• Craig A. Collard, Chief Executive Officer and Director of Heron Therapeutics, Inc. (HRTX), acquired 34,789 shares of common stock.
• This acquisition occurred on October 31, 2025, through the conversion of 34,789 Restricted Stock Units (RSUs).
• Following this transaction, Collard directly beneficially owns 523,124 shares of common stock.
• He also continues to beneficially own 452,253 Restricted Stock Units.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The Restricted Stock Units vest in 16 equal installments, with vesting commencing one quarter after the grant date of January 31, 2025.

Sentiment

Score: 7

Explanation: The conversion of Restricted Stock Units to common stock by the CEO increases his direct ownership, which can be interpreted as a positive signal of management's confidence in the company's future prospects. While it's a vesting event rather than an open market purchase, it still aligns the CEO's interests with shareholders.

Positives

• CEO Craig Collard increased his direct beneficial ownership of common stock by 34,789 shares, which can be interpreted as a signal of confidence in the company's future prospects.

Future Outlook

No specific forward-looking statements or guidance were provided beyond the vesting schedule of the Restricted Stock Units.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholders due to higher direct ownership of common stock.

Next Steps

• Continued vesting of the remaining 452,253 Restricted Stock Units in 16 equal installments, starting one quarter after January 31, 2025.

Key Dates

Recommendation

The CEO's conversion of Restricted Stock Units into common stock increases his direct stake in the company, which is generally viewed as a positive sign of confidence. However, this is a pre-scheduled vesting event rather than an open market purchase, and without additional financial or strategic information, it primarily reinforces a 'hold' position, suggesting continued monitoring of the company's performance and broader market conditions.

Keywords

Heron Therapeutics, HRTX, Craig Collard, Insider Transaction, Form 4, Restricted Stock Units, Common Stock, CEO, Director, Equity Conversion